

# Brianna N Lauren

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8908476/publications.pdf>

Version: 2024-02-01

10  
papers

185  
citations

1651377

6  
h-index

1762888

8  
g-index

12  
all docs

12  
docs citations

12  
times ranked

173  
citing authors

#	ARTICLE	IF	CITATIONS
1	Utility and Cost-Effectiveness of a Nonendoscopic Approach to Barrett's Esophagus Surveillance After Endoscopic Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e51-e63.	2.4	2
2	Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in borderline resectable/locally advanced pancreatic cancer patients. <i>Cancer Reports</i> , 2022, 5, e1565.	0.6	4
3	Estimated Cost-effectiveness of Medical Therapy, Sleeve Gastrectomy, and Gastric Bypass in Patients With Severe Obesity and Type 2 Diabetes. <i>JAMA Network Open</i> , 2022, 5, e2148317.	2.8	17
4	Endoscopic Screening Program for Control of Esophageal Adenocarcinoma in Varied Populations: A Comparative Cost-Effectiveness Analysis. <i>Gastroenterology</i> , 2022, 163, 163-173.	0.6	7
5	Predictors of households at risk for food insecurity in the United States during the COVID-19 pandemic. <i>Public Health Nutrition</i> , 2021, 24, 3929-3936.	1.1	86
6	Persistent effects of the COVID-19 pandemic on diet, exercise, risk for food insecurity, and quality of life: A longitudinal study among U.S. adults. <i>Appetite</i> , 2021, 167, 105639.	1.8	24
7	The cost-effectiveness of pharmacotherapy and lifestyle intervention in the treatment of obesity. <i>Obesity Science and Practice</i> , 2020, 6, 162-170.	1.0	26
8	Cost-Effectiveness Analysis of Biomarker-Guided Treatment for Metastatic Gastric Cancer in the Second-Line Setting. <i>Journal of Oncology</i> , 2020, 2020, 1-10.	0.6	10
9	Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in locally advanced/borderline resectable pancreatic cancer patients.. <i>Journal of Clinical Oncology</i> , 2020, 38, e16793-e16793.	0.8	0
10	Second-line treatment of metastatic gastric cancer in the era of predictive biomarkers: A cost-effectiveness analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, e15517-e15517.	0.8	0